Tag Archives: biotechnology law

Supreme Court Declines To Review “New And Improved” Written Description Requirement

On Tuesday, the Supreme Court denied Centocor’s (now “Janssen”) petition for cert. and so let stand a ruling that Centocor’s patents on humanized monoclonal antibodies (covering Abbott’s Humira) are invalid for failure to meet the written description requirement (WDR) of … Continue reading

Posted in Written Description Requirements (WDR) | Tagged , , , , , , , , , , , , , | Leave a comment

A “Modest Proposal” For The RCE Crisis

Commentators, including Prof. Hal Wegner, have been sounding the alarm regarding the increasing number of requests for continuing examination that applicants are filing. The PTO projects 325,000 RCE’s by FY 2018. They have gone further in recent posts, in attributing … Continue reading

Posted in AIA Patent Reform, USPTO Practice and Policy | Tagged , , , , , , , , , , , | Leave a comment

Top 2011 IP Stories on Patents4Life

I spent a day or two looking back over the breaking IP news that resulted in posts on Patents4Life. I wrote most of them, but want to take a pause to thank regular contributors Paul Cole, Ron Schutz and Stefan … Continue reading

Posted in Miscellaneous | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

AMP Petitions for Cert. and A Look Back

The Association for Molecular Pathology (AMP) has petitioned the Supreme Court to review the Fed. Cir.’s opinion of July 29th, that isolated BRCA DNA sequences are patentable subject matter. Its brief (a copy available at the end of this post) … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , , , , , , , , | 1 Comment